Public Employees Retirement System of Ohio Takes Position in Zoetis Inc. $ZTS

Public Employees Retirement System of Ohio purchased a new position in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 127,162 shares of the company’s stock, valued at approximately $9,138,000.

A number of other hedge funds have also recently made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis in the second quarter worth about $25,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after buying an additional 296 shares in the last quarter. Prosperity Bancshares Inc purchased a new position in shares of Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis in the 1st quarter worth approximately $28,000. Finally, Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $76.99 on Tuesday. The company has a market cap of $31.81 billion, a price-to-earnings ratio of 12.68, a PEG ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock’s fifty day moving average price is $75.59 and its 200 day moving average price is $95.04. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $156.49.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. UBS Group decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Finally, Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.